We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has reclassified electroconvulsive therapy (ECT) devices that treat catatonia or severe major depressive episodes or bipolar disorder as moderate risk devices with special controls. Read More
Under the agreement, Philips has agreed to continue service until Dec 31, 2022, and it will meet with the TGA twice yearly and report adverse events as required under normal operations. Read More